Guardant Health just unveiled nearly a dozen new capabilities for its Guardant360® Liquid blood test—turning a routine draw into a powerful tool for cancer profiling. Using AI and multiomic analysis, the test can now determine tumor origin, subtype, and even drug compatibility—all without needing tissue.
For colorectal cancer, the test can confirm the absence of actionable mutations, helping doctors skip additional tests and begin treatment faster. It also identifies key biomarkers, including those tied to HPV and EBV, and assesses pharmacogenomic safety for common therapies.